{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:31:55Z","timestamp":1785461515732,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12185-020-03075-6","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T09:05:51Z","timestamp":1610269551000},"page":"765-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia\/lymphoma with HTLV-1-associated myelopathy"],"prefix":"10.1007","volume":"113","author":[{"given":"Hikaru","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-3623","authenticated-orcid":false,"given":"Hidehiro","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sawayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Chiwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kitanosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Horai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiichiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,10]]},"reference":[{"key":"3075_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","volume":"1","author":"M Osame","year":"1986","unstructured":"Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1:1031\u20132.","journal-title":"Lancet"},{"issue":"11","key":"3075_CR2","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"K Ishitsuka","year":"2014","unstructured":"Ishitsuka K, Tamura K. Human T-cell Leukaemia Virus Type I and Adult T-cell Leukaemia-Lymphoma. Lancet Oncol. 2014;15(11):e517-526.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3075_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/leu.2008.272","volume":"23","author":"T Kozako","year":"2009","unstructured":"Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, et al. PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients. Leukemia. 2009;23(2):375\u201382.","journal-title":"Leukemia"},{"issue":"21","key":"3075_CR4","doi-asserted-by":"publisher","first-page":"11685","DOI":"10.1073\/pnas.1920346117","volume":"117","author":"M Nagasaka","year":"2020","unstructured":"Nagasaka M, Yamagishi M, Yagishita N, Araya N, Kobayashi S, Makiyama J, et al. Mortality and risk of progression to adult T cell leukemia\/lymphoma in HTLV-1-associated myelopathy\/tropical spastic paraparesis. Proc Natl Acad Sci USA. 2020;117(21):11685\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3075_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.leu.2403682","volume":"19","author":"T Fukushima","year":"2005","unstructured":"Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma. Leukemia. 2005;19(5):829\u201334.","journal-title":"Leukemia"},{"issue":"9","key":"3075_CR6","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","volume":"119","author":"J Kanda","year":"2012","unstructured":"Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119(9):2141\u20138.","journal-title":"Blood"},{"issue":"1","key":"3075_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2012-07-444372","volume":"121","author":"H Itonaga","year":"2013","unstructured":"Itonaga H, Tsushima H, Taguchi J, Fukushima T, Taniguchi H, Sato S, et al. Treatment of relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group Experience. Blood. 2013;121(1):219\u201325.","journal-title":"Blood"},{"key":"3075_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3389\/fimmu.2019.01570","volume":"10","author":"R Greco","year":"2019","unstructured":"Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, et al. Allogeneic HSCT for autoimmune diseases: a retrospective study From the EBMT ADWP, IEWP, and PDWP Working Parties. Front Immunol. 2019;10:1570.","journal-title":"Front Immunol"},{"issue":"8","key":"3075_CR9","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for Risk Assessment Before Allogeneic HCT. Blood. 2005;106(8):2912\u20139.","journal-title":"Blood"},{"issue":"4","key":"3075_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.bbmt.2017.11.005","volume":"24","author":"M Yoshimitsu","year":"2018","unstructured":"Yoshimitsu M, Tanosaki R, Kato K, Ishida T, Choi I, Takatsuka Y, et al. Risk Assessment in Adult T Cell Leukemia\/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018;24(4):832\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3075_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10428194.2016.1187270","volume":"58","author":"M Tokunaga","year":"2017","unstructured":"Tokunaga M, Uto H, Takeuchi S, Nakano N, Kubota A, Tokunaga M, et al. Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2017;58(1):37\u201344.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3075_CR12","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/WNL.46.4.1016","volume":"46","author":"S Izumo","year":"1996","unstructured":"Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology. 1996;46(4):1016\u201321.","journal-title":"Neurology"},{"issue":"5","key":"3075_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr, O\u2019leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549\u201357.","journal-title":"J Urol."},{"issue":"10","key":"3075_CR14","doi-asserted-by":"publisher","first-page":"e2479","DOI":"10.1371\/journal.pntd.0002479","volume":"7","author":"T Sato","year":"2013","unstructured":"Sato T, Coler-Reilly A, Utsunomiya A, Araya N, Yagishita N, Ando H, et al. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy\/tropical spastic paraparesis. PLoS Negl Trop Dis. 2013;7(10):e2479.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"3075_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/blood.V99.1.88","volume":"99","author":"Y Yamano","year":"2002","unstructured":"Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, et al. Correlation of human T-cell Lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM\/TSP). Blood. 2002;99(1):88\u201394.","journal-title":"Blood"},{"issue":"4","key":"3075_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12185-012-1020-2","volume":"95","author":"S Kamihira","year":"2012","unstructured":"Kamihira S, Iwanaga M, Doi Y, Sasaki D, Mori S, Tsurda K, et al. Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: continuity from carrier status to smoldering ATL. Int J Hematol. 2012;95(4):399\u2013408.","journal-title":"Int J Hematol."},{"issue":"3","key":"3075_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453\u20139.","journal-title":"J Clin Oncol"},{"issue":"34","key":"3075_CR18","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458\u201364.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3075_CR19","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2004-11-4193","volume":"105","author":"J Okamura","year":"2005","unstructured":"Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma. Blood. 2005;105(10):4143\u20135.","journal-title":"Blood"},{"issue":"6","key":"3075_CR20","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/sj.leu.2404678","volume":"21","author":"R Yamasaki","year":"2007","unstructured":"Yamasaki R, Miyazaki Y, Moriuchi Y, Tsutsumi C, Fukushima T, Yoshida S, et al. Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult t-cell leukemia\/lymphoma. Leukemia. 2007;21(6):1212\u20137.","journal-title":"Leukemia"},{"issue":"7","key":"3075_CR21","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1073\/pnas.96.7.3848","volume":"96","author":"KJ Jeffery","year":"1999","unstructured":"Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A. 1999;96(7):3848\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3075_CR22","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.4049\/jimmunol.165.12.7278","volume":"165","author":"KJ Jeffery","year":"2000","unstructured":"Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol. 2000;165(12):7278\u201384.","journal-title":"J Immunol"},{"issue":"7","key":"3075_CR23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1086\/342953","volume":"186","author":"AM Vine","year":"2002","unstructured":"Vine AM, Witkover AD, Lloyd AL, Jeffery KJ, Siddiqui A, Marshall SE, et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy\/tropical spastic paraparesis. J Infect Dis. 2002;186(7):932\u20139.","journal-title":"J Infect Dis"},{"issue":"1\u20132","key":"3075_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jneuroim.2004.07.007","volume":"156","author":"D Kodama","year":"2004","unstructured":"Kodama D, Saito M, Matsumoto W, Sabouri AH, Izumo S, Arimura K, et al. Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). J Neuroimmunol. 2004;156(1\u20132):188\u201394.","journal-title":"J Neuroimmunol"},{"issue":"7","key":"3075_CR25","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1086\/423942","volume":"190","author":"AH Sabouri","year":"2004","unstructured":"Sabouri AH, Saito M, Lloyd AL, Vine AM, Witkover AW, Furukawa Y, et al. Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis. J Infect Dis. 2004;190(7):1279\u201385.","journal-title":"J Infect Dis"},{"issue":"12","key":"3075_CR26","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/sj.bmt.1702067","volume":"24","author":"JE Dowell","year":"1999","unstructured":"Dowell JE, Moots PL, Stein RS. Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma. Bone Marrow Transplant. 1999;24(12):1359\u201361.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"3075_CR27","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/blood-2016-05-715342","volume":"128","author":"Y Inamoto","year":"2016","unstructured":"Inamoto Y, Martin PJ, Flowers ME, Lee SJ, Carpenter PA, Warren EH, et al. Genetic risk factors for sclerotic graft-versus-host disease. Blood. 2016;128(11):1516\u201324.","journal-title":"Blood"},{"issue":"3","key":"3075_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00430-017-0492-3","volume":"206","author":"T Rajaei","year":"2017","unstructured":"Rajaei T, Farajifard H, Rafatpanah H, Bustani R, Valizadeh N, Rajaei B, et al. Role of IL-21 in HTLV-1 infections with emphasis on HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). Med Microbiol Immunol. 2017;206(3):195\u2013201.","journal-title":"Med Microbiol Immunol"},{"issue":"4","key":"3075_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1089\/vim.2016.0152","volume":"30","author":"HVPC Neco","year":"2017","unstructured":"Neco HVPC, Teixeira VGS, Trindade ACL, Magalh\u00e3es PMR, Lorena VMB, Vasconcelos LR, et al. IL17A polymorphism is not associated with human T-lymphotropic virus 1-associated myelopathy\/tropical spastic paraparesis. Viral Immunol. 2017;30(4):298\u2013301.","journal-title":"Viral Immunol"},{"key":"3075_CR30","doi-asserted-by":"publisher","first-page":"15012","DOI":"10.1038\/nrdp.2015.12","volume":"1","author":"CR Bangham","year":"2015","unstructured":"Bangham CR, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy\/tropical spastic paraparesis. Nat Rev Dis Primers. 2015;1:15012.","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"3075_CR31","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377(26):2565\u201379.","journal-title":"N Engl J Med"},{"issue":"5","key":"3075_CR32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s13365-020-00881-w","volume":"26","author":"S Nozuma","year":"2020","unstructured":"Nozuma S, Kubota R, Jacobson S. Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy\/tropical spastic paraparesis. J Neurovirol. 2020;26(5):652\u201363.","journal-title":"J Neurovirol"},{"issue":"4","key":"3075_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s004010050903","volume":"96","author":"E Matsuoka","year":"1998","unstructured":"Matsuoka E, Takenouchi N, Hashimoto K, Kashio N, Moritoyo T, Higuchi I, Isashiki Y, Sato E, Osame M, Izumo S. Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy\/tropical spastic paraparesis: double staining of immunohistochemistry and polymerase chain reaction in situ hybridization. Acta Neuropathol. 1998;96(4):340\u20136.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"3075_CR34","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1172\/JCI39165","volume":"120","author":"S Asakura","year":"2010","unstructured":"Asakura S, Hashimoto D, Takashima S, Sugiyama H, Maeda Y, Akashi K, et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest. 2010;120(7):2370\u20138.","journal-title":"J Clin Invest"},{"issue":"3","key":"3075_CR35","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","volume":"171","author":"BR Lazar","year":"2003","unstructured":"Lazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272\u20137.","journal-title":"J Immunol."},{"issue":"3","key":"3075_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/13550280152403272","volume":"7","author":"T Matsuzaki","year":"2001","unstructured":"Matsuzaki T, Nakagawa M, Nagai M, Usuku K, Higuchi I, Arimura K, et al. HTLV-I proviral load correlates with progression of motor disability in HAM\/TSP: analysis of 239 HAM\/TSP patients including 64 patients followed up for 10 years. J Neurovirol. 2001;7(3):228\u201334.","journal-title":"J Neurovirol"},{"issue":"1\u20132","key":"3075_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2005.05.010","volume":"237","author":"S Olindo","year":"2005","unstructured":"Olindo S, L\u00e9zin A, Cabre P, Merle H, Saint-Vil M, Edimonana Kaptue M, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM\/TSP patients: a marker of disease progression. J Neurol Sci. 2005;237(1\u20132):53\u20139.","journal-title":"J Neurol Sci"},{"issue":"5","key":"3075_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00007890-198411000-00011","volume":"38","author":"D Niederwieser","year":"1984","unstructured":"Niederwieser D, Huber C, Gratwohl A, Bannert P, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation. 1984;38(5):497\u2013500.","journal-title":"Transplantation."},{"issue":"9","key":"3075_CR39","first-page":"699","volume":"5","author":"RM Giusti","year":"1996","unstructured":"Giusti RM, Maloney EM, Hanchard B, Morgan OS, Steinberg SM, et al. Differential patterns of serum biomarkers of immune activation in human ccc lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis, and adult T-cell leukemia\/lymphoma. Cancer Epidemiol Biomark Prev. 1996;5(9):699\u2013704.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"24","key":"3075_CR40","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2015-09-668251","volume":"127","author":"A Kariminia","year":"2016","unstructured":"Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. Blood. 2016;127(24):3082\u201391.","journal-title":"Blood"},{"issue":"11","key":"3075_CR41","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47(11):1304\u201315.","journal-title":"Nat Genet"},{"issue":"23","key":"3075_CR42","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood.2019002665","volume":"135","author":"AG Rowan","year":"2020","unstructured":"Rowan AG, Dillon R, Witkover A, Melamed A, Demontis MA, Gillet NA, et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia\/lymphoma diagnosis. Blood. 2020;135(23):2023\u201332.","journal-title":"Blood"},{"issue":"7","key":"3075_CR43","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood.2019003084","volume":"136","author":"T Watanabe","year":"2020","unstructured":"Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, et al. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100. Blood. 2020;136(7):871\u201384.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-03075-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T10:06:34Z","timestamp":1620209194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-03075-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3075"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03075-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,10]]},"assertion":[{"value":"3 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. Miyazaki has received honoraria from Otsuka Pharma, Novartis Pharma, Nippon-Shinyaku Co, Sumitomo Dainippon Pharma, and Kyowa Hakko Kirin Co and research funding from Chugai Pharma. S. Yoshida has received grants from Chugai Pharma and Kyowa-Kirin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Committees of Nagasaki University Hospital (approval no. 18061816 and 18061804) and St. Marianna University School of Medicine (approval no. 1646) at which this study was organized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}